Haemonetics reports Q2 adjusted EPS $1.12, consensus $1.07

Reports Q2 revenue $345.51M, consensus $342.65M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Strong second-quarter performance reflects progress executing our long-range plan and responding to market trends. We have evolved our portfolio to attractive products with meaningful demand to drive growth and margin expansion. We are advancing our leading positions to accelerate profitable growth in the second half of our fiscal year and beyond.”